Drug intelligence / Profile preview

belantamab mafodotin + elotuzumab

Development stage: Unknown
Lead developer: GSK
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Belantamab mafodotin + elotuzumab is an investigational combination therapy being evaluated for the treatment of relapsed or refractory multiple myeloma. Belantamab mafodotin is a B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate (ADC) that delivers the cytotoxic agent monomethyl auristatin F (MMAF) directly to plasma cells, inducing apoptosis and enhancing immune-mediated cell death. Elotuzumab is a humanized monoclonal antibody targeting Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7), which activates Natural Killer (NK) cells and tags myeloma cells for antibody-dependent cellular cytotoxicity (ADCC). This combination, currently being studied in the Phase Ib/II Bela-Elo trial sponsored by Yale University in collaboration with GSK, aims to leverage synergistic immune-mediated mechanisms to overcome resistance in heavily pretreated, triple-class refractory patients.

Brand names: BlenrepEmpliciti
Other names: belantamab mafodotin-blmfBela-Elo

Targets

SLAMF7 (Signaling lymphocytic activation molecule family member 7)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on belantamab mafodotin + elotuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on belantamab mafodotin + elotuzumab.

Explore the full profile